

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02853 A3

(51) International Patent Classification⁷: G01N 33/86

[BE/BE]; Ommegangstraat 3, B-8550 Zwevegem (BE).
DECKMYN, Hans [BE/BE]; Lemingstraat 1, B-3210
Linden (BE).

(21) International Application Number: PCT/EP00/06345

(22) International Filing Date: 5 July 2000 (05.07.2000)

(74) Agent: VOSSIUS & PARTNER; Siebertstr. 4, D-81675
München (DE).

(25) Filing Language: English

(81) Designated States (national): JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(30) Priority Data:
99112967.7 5 July 1999 (05.07.1999) EP

Published:

— With international search report.

(71) Applicant (for all designated States except US): ROCHE
DIAGNOSTICS GMBH [DE/DE]; Sandhofer Strasse
116, D-68305 Mannheim (DE).


(88) Date of publication of the international search report:
12 July 2001

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAUWEN-
BERGHS, Nancy [BE/BE]; Benningsbrugstraat 56A,
B-9032 Gent (BE). VANHOORELBEKE, Karen

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY



(57) Abstract: The present invention relates to a method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib(α) (GPIb(α)) and ristocetin, or a functionally equivalent substance. Additionally, the invention relates to the use of the aforementioned soluble form or portion of glycoprotein Ib(α), of ristocetin or a functional equivalent substance, of specifically reacting anti-GPIb(α) antibody(ies) and/or of specific binding partners, like specifically reacting anti-vWF antibody(ies) for carrying out the method of the invention. Furthermore, the present invention relates to kits for carrying out the method of the invention.

WO 01/02853 A3